Background-The prognosis and treatment of patients with low-flow (LF) severe aortic stenosis are controversial. Methods and Results-The Placement of Aortic Transcatheter Valves (PARTNER) trial randomized patients with severe aortic stenosis to medical management versus transcatheter aortic valve replacement (TAVR; inoperable cohort) and surgical aortic valve replacement versus TAVR (high-risk cohort). Among 971 patients with evaluable echocardiograms (92%), LF (stroke volume index ≤35 mL/m 2 ) was observed in 530 (55%); LF and low ejection fraction (<50%) in 225 (23%); and LF, low ejection fraction, and low mean gradient (<40 mm Hg) in 147 (15%). Two-year mortality was significantly higher in patients with LF compared with those with normal stroke volume index (47% versus 34%; hazard ratio, 1.5; 95% confidence interval, 1.25-1.89; P=0.006). In the inoperable cohort, patients with LF had higher mortality than those with normal flow, but both groups improved with TAVR (46% versus 76% with LF and 38% versus 53% with normal flow; P<0.001). In the high-risk cohort, there was no difference between TAVR and surgical aortic valve replacement. In patients with paradoxical LF and low gradient (preserved ejection fraction), TAVR reduced 1-year mortality from 66% to 35% (hazard ratio, 0.38; P=0.02). LF was an independent predictor of mortality in all patient cohorts (hazard ratio, ≈1.5), whereas ejection fraction and gradient were not. 
A ortic valve replacement (AVR) is indicated for patients with severe aortic stenosis (AS) associated with either symptoms or left ventricular (LV) dysfunction. 1, 2 Severe AS is generally defined as an aortic valve area ≤1.0 cm 2 and a mean transvalvular gradient of ≥40 mm Hg. However, many patients with symptomatic and severe AS may have lower gradients resulting from LV systolic dysfunction (so-called low flow [LF] , low ejection fraction [LEF] ), high afterload with pronounced LV concentric remodeling (paradoxical LF, normal ejection fraction [NEF]), and from errors or assumptions inherent in the measurement of gradient and valve area. [3] [4] [5] [6] [7] These patients have a prognosis similar to or worse than that for patients with classic AS, both with and without surgery. [6] [7] [8] [9] [10] [11] [12] [13] [14] However, little is known about the prognostic value of LF independently of gradient and EF and its treatment.
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Transcatheter AVR (TAVR) has recently emerged as an alternative to open surgical AVR (SAVR) in both inoperable and high-risk patients with severe AS. [15] [16] [17] [18] To better understand the implications of LF in severe AS, we used core echocardiographic laboratory data to examine the prognostic implications of LF, low gradient (LG), and LEF in the prospective, randomized Placement of Aortic Transcatheter Valves (PARTNER) trial and to examine the comparative benefits of medical management (MM), SAVR, and TAVR.
Methods

Study Population
The PARTNER trial was a multicenter, randomized, clinical trial comparing TAVR with standard therapy (SAVR) in high-risk patients (cohort A) 16 and included a prespecified cohort of patients who were not considered to be suitable candidates for surgery (inoperable; cohort B). 15 All patients had symptoms (New York Heart Association classes II-IV) and severe AS. Inclusion criteria for this trial included a site-measured echocardiographic aortic valve area of <0.8 cm 2 (or indexed aortic valve area <0.5 cm 2 /m 2 ) and either a mean transvalvular gradient ≥40 mm Hg or a peak aortic jet velocity ≥4.0 m/s (64 mm Hg). Important exclusion criteria included substantial coronary artery disease requiring revascularization, EF <20%, or severe (4+) aortic or mitral regurgitation. Patients were treated with the Edwards SAPIEN balloonexpandable bovine pericardial heart valve system (Edwards Lifesciences). The primary end point for the study (both cohorts) was all-cause mortality at ≥1 year, but follow-up has continued, allowing subsequent analyses with adjudicated events. 17, 18 All echocardiograms were analyzed by an independent core laboratory. 19 The database for the study is maintained at the Cardiovascular Research Foundation (New York, NY), where independent statistical analyses can be requested by investigators.
In this analysis, patients with evaluable echocardiograms were classified into 2 groups based on baseline echocardiographic stroke volume index (SVI) of ≤35 mL/m 2 (LF) or normal flow (NF). 2, 4 The LF group was then further divided on the basis of EF <50% (LF LEF) or normal EF (LF NEF) and gradient <40 mm Hg (LF LG) or ≥40 mm Hg (LF with normal gradient; Figure 1 ). In all groups, patients were analyzed by cohort (cohort A, high risk; cohort B, inoperable) and treatment received (MM, SAVR, or TAVR).
Echocardiographic Measurements
All baseline and follow-up echocardiograms were interpreted by an independent core laboratory housed at the Duke Clinical Research Institute. Study work flow, reproducibility testing, image acquisition and analysis, and quality assurance data have been published. 19 All chamber parameters were measured in standard views according to the recommendations of the American Society of Echocardiography. 20 LV volumes and EFs were measured with the biplane Simpson volumetric method combining apical 4-chamber and 2-chamber views when possible; if image quality was inadequate, EF was estimated visually in 5-percentage-point increments. Stroke volume and cardiac output were calculated by Doppler using the velocity-time integral of the LV outflow tract and its diameter in midsystole of the aortic annulus in the parasternal long-axis view. 19, 20 
Statistical Analysis
All analyses were performed with data from the intentionto-treat population, which included all patients who underwent randomization, regardless of the treatment actually received. However, only patients with echocardiographic data to allow classification by stroke volume could be included in this report (971 patients, 92%). Categorical variables were compared with the use of the Fisher exact test or χ 2 test. Continuous variables are presented as mean±SD or median (interquartile range) for variables with a skewed distribution and compared with the use of the Wilcoxon rank-sum test. Survival curves for time-to-event variables were constructed on the basis of all available follow-up data with the use of KaplanMeier estimates and were compared with the use of the log-rank test. Multivariable analysis was performed with the Cox proportional hazards model. We examined univariate predictors of mortality for 5 baseline echocardiographic variables relating to flow (LF, LG, LEF, aortic regurgitation, mitral regurgitation). Significant variables were then examined in pairwise analyses with each other and in several adjusted multivariable models in the various patient cohorts. Baseline variables entered into the multivariate Cox regression for adjustment were those that showed a statistically significant difference between the LF and NF groups. All statistical analyses were performed with the use of SAS software (version 9.2). Figure 1 ). LG (≤40 mm Hg) was present in 45% of patients, and aortic valve area >0.8 cm 2 was present in 19% of patients. Patients with LF were of an age (84 years) similar to that of patients with NF but were more likely to be male (59% compared with 47%) and had slightly higher Society of Thoracic Surgeons (STS) risk scores and logistic EUROscores. The LF group had more comorbid conditions, including coronary disease, prior pacemaker, a trend to more heart failure symptoms, and higher pulmonary artery and capillary wedge pressures, than those with NF. Procedure success was similar in the 2 groups, with a slightly longer length of stay for those with LF. Patients with LF had numerous echocardiographic differences compared with those with NF, including larger LV size (both diastolic and systolic), lower EF, lower gradient, lower calculated aortic valve areas, less aortic regurgitation, and more mitral regurgitation (Table 1) . At 30 days of follow-up, there were nonsignificant trends to greater all-cause mortality in patients with LF compared with NF. For subsequent analyses, the patients with LF were further subdivided on the basis of an LVEF <50% or ≥50% and gradient ≤40 or >40 mm Hg. LF and LEF (mean EF, 37±9%) were present in 225 patients (23% of the total study population), and 147 of these patients also had a low mean transvalvular gradient (mean gradient, 29±7 mm Hg, 15% of total population; Figure 1 ). Paradoxical LF with NEF was present in 304 patients (31% of the total population), and 139 of these patients also had LG (14% of the total population). Patients with LF and NEF had smaller LV end-diastolic volume (100 mL) than those with LEF (149 mL; P<0.0001).
Mortality of Patients With LF Severe AS
When the intention-to-treat combined (inoperable and highrisk) cohorts of the PARTNER trial were used, all-cause mortality at 2 years was higher in patients with LF versus NF (47.1% versus 33.7%; hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.28-1.95; P<0.0001; Figure 2A ). There was no additional increase in mortality when the LF patients were further divided into those with LEF and those with NEF ( Figure 2B ) and those with LG versus those with normal gradient ( Figure 2C ), although the overall mortality in all of these subgroups remained high, approximating 50% at 2 years. A sensitivity analysis revealed no difference with a cut point for EF of 40% (HR, 1.07; P=0.647) versus an EF of 50% (HR, 1.07; P=0.606).
Effect of TAVR and SAVR on Outcome in LF Severe AS
Treatment with both open surgery and TAVR in LF patients was associated with a marked improvement in both 1-year and 2-year survival ( Figure 3 ). Compared with MM, which had a 2-year mortality of 76%, the mortality with TAVR and SAVR ranged from 38% to 46%. The difference between MM and TAVR in the inoperable cohort was statistically significant (relative risk, 0.49; 95% CI, 0.33-0.72; P=0.0002; Figure 3A ), whereas there was no significant difference between TAVR and SAVR in the high-risk group (relative risk, 0.86; 95% CI, 0.58-1.29; P=0.47; Figure 3B ). There was a small early hazard associated with SAVR in the first 30 days. After 30 days, the mortality curves in the high-risk group of 
Comparison of Effects of AVR in LF Versus NF Severe AS
Patients with LF are compared with those with NF in Figure 5 .
In the high-risk cohort, it is apparent that the patients with LF had higher mortality than the NF patients at 2 years both with TAVR (40% versus 25%) and with SAVR (38% versus 29%; Figure 5A ). In the inoperable group of patients, the absolute difference in mortality between MM and TAVR was greater in the LF patients (76.2% versus 45.9%) than in the NF group (54.7% versus 38.5%), although the risk reductions were similar ( Figure 5B ).
Results in Patients With Paradoxical LF and Normal EF
The results of treatment on mortality in LF NEF (mean EF, 58±5%) patients are shown in Figure 6 and in Figure II Figure II in the online-only Data Supplement).
For patients with LF, NEF, and LG (Figure 6 ), the difference between MM and TAVR in inoperable patients was significant 
Multivariable Analysis
For the combined cohorts, both LF and LG were significant univariate predictors of 1-year (Table I in the online-only Data Supplement) and 2-year (Table 2 ) mortality, whereas baseline aortic regurgitation, mitral regurgitation, and LEF were not significant. In a pairwise multivariable analysis of LF and LG, only LF was an independent predictor of an increase in mortality. Adding other baseline variables into the model resulted in the following multivariable predictors of 2-year mortality: LF (HR, 1.44; P=0.0006), higher STS risk score (HR, 1.06; P<0.0001), and major arrhythmia (HR, 1.31; P=0.0086).
In the high-risk operable cohort A, the only univariate echocardiographic predictor of 1-year mortality was LF (HR, 1.43; P=0.0287; Table I in the online-only Data Supplement). At 2 years, univariate predictors included LF and LG. In multivariable analysis, STS risk score and major arrhythmia were predictors of 1-year mortality, and LF, STS risk score, and major arrhythmia were predictors of 2-year mortality (Table 2) .
Finally, in the inoperable cohort B, univariate predictors of increased 1-year mortality included LF and LEF, but LF was the only significant variable at 2 years and when analyzed pairwise with either LG or LEF (Table 2 ). In multivariable analysis, the significant predictors at both 1 and 2 years were LF, body mass index, STS risk score, new permanent pacemaker for increased mortality, and TAVR for improved survival.
Discussion
The major findings of this study are as follows. First, in patients with severe AS, LF, defined by a SVI ≤35 mL/m 2 , is associated with a significant 50% increase in 2-year all-cause mortality compared with patients with NF. Second, the impact of LF on subsequent mortality was independent in multivariable analysis and was a more powerful predictor of outcome than EF or mean transvalvular gradient. Third, patients with severe AS and LF and those with concomitant LEF and LG treated with TAVR had improved survival compared with patients treated medically. Fourth, in both the inoperable and high-risk cohorts of PARTNER, LF patients had a worse prognosis than NF patients but experienced similar benefits with therapy (TAVR was better than MM for inoperable patients and TAVR was similar to SAVR in high-risk patients). Fifth, patients with paradoxical LF (NEF, with normal gradient or LG) also had a worse prognosis, improvement with therapy compared with MM, and similar outcomes with TAVR versus SAVR. Taken together, these findings suggest that an assessment of LF based on SVI may be useful in the evaluation of all patients with severe AS. In addition, surgery and transcatheter AVR should be considered in patients with LF despite their increased mortality compared with NF patients.
Pathophysiology of LF
LF AS with LG has classically been further categorized by the EF. Among patients with LEF, LF may be attributed to poor contractile function of the LV. More recently, Hachicha and colleagues 4 described a cohort of patients with LF AS with
LG but with an EF of at least 50%, called paradoxical LF AS. Although these patients typically have slightly lower EFs than their comparators with NF and normal gradients, the LF in these cases has been attributed to higher global LV afterload, a restrictive physiology with pronounced LV concentric hypertrophy, and reduced LV compliance and filling. 7, 21, 22 It may also be associated with greater subendocardial fibrosis and reduced longitudinal deformation. 23 Nonrandomized data suggest that regardless of the origin, patients with LF AS with LG have worse outcomes with and without surgery yet may still benefit from valve replacement compared with MM. 6, [8] [9] [10] [11] [12] [13] [14] In our analysis of patients with severe AS and predominantly not LGs, a low stroke volume was an important independent predictor of midterm all-cause mortality compared with patients with NF. Although current guidelines emphasize the importance of EF in the evaluation of patients with AS for surgery even when asymptomatic, our data suggest that EF may be less important after adjustment for flow. A unifying hypothesis for these findings is that a low forward output from the LV, whether a result of afterload mismatch with Time in Days   0  6 0  120  180  240  300  360  420  480  540  600  660  720   85  74  65  58  55  50  47  46  46  95  78  60  47  39  35  26  25  18  78  67  60  59  56  53  51  49  47  66  55  49  43  39  38  32  26 high impedance, impaired myocardial contractility, restrictive physiology, or other mechanism, is a more important determinant of outcome than the mechanism for the decrease in flow.
Further study may help to elucidate whether a specific SVI or change in stroke volume should be used to guide the timing of valve replacement.
Benefit of AVR in LF Severe AS
Several nonrandomized studies have sought to elucidate the impact of an LF state on surgical outcome in patients with severe AS. Patients with LEF and LF AS have poorer outcomes, often stratified according to the hemodynamic response to dobutamine and whether the LV exhibits contractile reserve. 7, 9, 12 Patients with flow reserve are more likely to improve with valve replacement, whereas results for those without flow reserve have varied. Previous studies are limited by various definitions for LF, gradient, and valve area, as well as the biases associated with cohort studies. Our analysis is the first to include randomization, and we found a significant benefit from valve replacement. Whether this should affect the decision to intervene, suggesting that valve replacement be based on SVI or the response of SVI to dobutamine (flow reserve) rather than EF, may require further prospective evaluation.
The current American College of Cardiology/American Heart Association guidelines, first published in 2006, have no specific recommendation on the indication for AVR in patients with LF AS with LG. 1 The recent European Society of Cardiology guidelines state that AVR should be considered (Class IIa) in symptomatic patients with classic LF AS (LF, LG, and LEF) if there is evidence of flow or contractile reserve. 2 In addition, a new recommendation (Class IIa) is included for symptomatic patients with paradoxical LF AS with LG (preserved EF). LF was defined as in this study (SVI ≤35 mL/m 2 ). Because of the limited data on the natural history and outcome of surgery in these patients, the level of evidence was C. 2 The data in the present study provide new evidence for these recommendations and stress the importance of measuring and reporting SVI in patients with severe AS.
The finding that early survival is improved with TAVR versus SAVR in LF severe AS is intriguing. Possible explanations include the less invasive nature of TAVR, detrimental effects of Time in Days   0  6 0  120  180  240  300  360  420  480  540  600  660  720   43  39  38  34  34  33  29  27  26  44  33  30  30  28  28  28  27 by guest on June 9, 2017
http://circ.ahajournals.org/ cardiopulmonary bypass on patients with limited flow or contractile reserve, and larger effective orifice area with SAPIEN TAVR compared with standard bioprostheses. In 1 nonrandomized comparison of TAVR and SAVR in patients with LEF, there did appear to be better recovery of EF with TAVR compared with SAVR. 14 One possible explanation for this finding may involve the heightened afterload sensitivity of patients with LF, LG, and LEF to the effects of patient-prosthesis mismatch. 10, [24] [25] [26] In the Clavel et al 14 study, the indexed aortic valve area after the procedure was larger with TAVR than with SAVR; however, in our study, we found no difference in the discharge indexed aortic valve area in LF patients.
Paradoxical LF Severe AS
The impact of paradoxical LF, LG severe AS with an NEF has been debated. Several studies have suggested that these patients have a poorer prognosis and improved survival after surgery. 4, 6, 7, 13, 14 However, a substudy of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial found that outcomes in asymptomatic patients with LF were no worse than in those with NF. 27 Treatment decisions in these studies were not randomized, and patients in the Jander et al 27 study were asymptomatic with less severe AS. Nonetheless, aortic valve events occurred in almost 50% of the LF group within 5 years.
Our findings confirm the high frequency and worse prognosis of symptomatic patients with LF severe AS and preserved ventricular function. We also demonstrate that these patients derive significant and similar benefit with transcatheter and surgical valve replacement and that this benefit is observed in patients with both high gradients and LGs. Our analysis is the first to compare outcomes in this patient population in a randomized trial with centrally adjudicated core echocardiographic laboratory measures and the first to demonstrate an improvement in survival with TAVR compared with MM. Unlike prior studies, EF was not a differentiating factor in the prognosis of LF patients in our study, suggesting that flow, rather than the mechanism for reduced flow, is the key prognostic factor.
Clinical Implications
It is well established that standard parameters of AS severity, including aortic valve area, whether measured in the cardiac catheterization laboratory or with echocardiography, vary with flow. 3 A more comprehensive evaluation of AS severity may include the use of valvular resistance, 5, 28 valvulo-arterial impedance, 21, 22 or projected valve area at NF. 25 Although these measures add utility in a comprehensive evaluation of AS, our findings suggest that SVI should be included in the assessment of patients with severe AS.
Stroke volume may vary with changes in loading conditions, volume status, and other patient factors. Yet relying on EF may be misleading because the stroke volume associated with a particular EF may vary from one patient to another, depending on the ventricular size, volume status, systemic arterial resistance and compliance, and other variables. 22 A comprehensive approach to patient assessment is warranted, and stroke volume is a crucial piece of information to determine prognosis and to inform treatment decisions. It may be particularly important in symptomatic patients with LG, in whom decision making with regard to valve replacement is more difficult.
Limitations
We analyzed LF using the Doppler-derived 2-dimensional LV outflow tract diameter and velocity-time integral. The definition of LF is not standardized in the literature, but we chose a definition (SVI ≤35 mL/m 2 ) that has been commonly used 4 ,6,7,13,14,22 and was included in the recent European Society of Cardiology guidelines. 2 We also performed sensitivity and specificity testing of various SVI values for mortality, and 35 mL/m 2 was nearly optimal in a receiver-operating characteristic curve analysis. It is possible that a 3-dimensional echocardiographic or computed tomography assessment of the outflow tract dimensions or invasive hemodynamic assessment could lead to different values and conclusions. 5, 29, 30 The velocity-time integral assessed by LV outflow tract flow may also be directly affected by the presence of aortic regurgitation and indirectly by mitral regurgitation, both of which differed in prevalence at baseline between LF and NF subjects. Nonetheless, neither aortic nor mitral regurgitation had an independent predictive value for subsequent mortality.
Our analysis was retrospective and subject to the limitations of an observational study. Treatment was not prospectively randomized in any of the LF subgroups, and the comparisons and conclusions should be validated in a prospective trial. Nonetheless, it is an analysis of a large, randomized study with core laboratory echocardiographic data and thus is the largest available database of patients with severe AS in which to examine the impact of LF on outcome and therapy. The findings of dobutamine stress echocardiographic evaluation performed in some of the PARTNER trial patients with LG would be of interest for this study but were not collected prospectively and were not available for this analysis. Finally, our results cannot be extrapolated to patients with severe obstructive coronary artery disease, who were not included in the PARTNER trial.
Conclusions
LF, defined by the echocardiographic SVI ≤35 mL/m 2 , is a surprisingly common finding in patients with severe AS. It is a more powerful predictor of subsequent mortality than either EF or mean gradient. In patients with severe AS, LF with both LEF and NEF is associated with increased 2-year mortality compared with patients with NF. TAVR improves survival compared with MM and provides a similar outcome compared with SAVR. An assessment of flow (SVI) should be included in the evaluation and therapeutic decision making of patients with severe AS.
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